ReviewsT-Cell Immunity in Pancreatic CancerAjina, Reham PhD; Weiner, Louis M. MDAuthor Information From the Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Received for publication January 9, 2020; accepted June 20, 2020. Address correspondence to: Louis M. Weiner, MD, Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown Cancer Institute, Department of Oncology, Georgetown University School of Medicine, 3970 Reservoir Rd, NW, Washington, DC 20057 (e-mail: firstname.lastname@example.org). This research was supported by NCI R01 CA50633 (L.M.W.) and National Institutes of Health (NIH)/National Cancer Institute (NCI) Grant P30-CA051008. R.A. was supported by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) and the Saudi Arabian Cultural Mission (SACM). The authors declare no conflict of interest. Pancreas: September 2020 - Volume 49 - Issue 8 - p 1014-1023 doi: 10.1097/MPA.0000000000001621 Buy Metrics Abstract Worldwide, approximately half a million people are diagnosed with pancreatic cancer every year, with mortality rates of more than 90%. T cells within pancreatic tumors are generally infrequent and incapable of eliciting antitumor immunity. Thus, pancreatic cancer is considered an “immunologically cold” tumor. However, recent studies clearly show that when T-cell immunity in pancreatic cancer is sufficiently induced, T cells become effective weapons. This fact suggests that to improve pancreatic cancer patients' clinical outcomes, we need to unveil the complex immune biology of this disease. In this review, we discuss the elements of tumor immunogenicity in the specific context of pancreatic malignancy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.